Skip to main content
. 2022 Jun 9;19(12):7103. doi: 10.3390/ijerph19127103

Table 1.

Values are reported as mean values for the continuous variables and percentages for the categorical variables. Statistical significance was assessed by p value (p) thresholds: ** p < 0.01; *** p < 0.001 (t-test analysis).

Characteristics Control Group Long-COVID
Overall (n = 45) Male (n = 22) Female (n = 23) Overall (n = 48) Male (n = 34) Female (n = 14)
Age (years) 60.62 ± 17.37 62.31 ± 18.78 59.50 ± 16.35 62.54 ± 10.18 62.90 ± 9.22 61.69 ± 12.57
BMI 26.04 ± 3.43 26.32 ± 2.68 25.77 ± 4.05 27.91 ± 4.26 28.46 ± 4.05 27.14 ± 4.02
LDH (UI/L) 189.33 ± 42.36 192.00 ± 38.99 187.00 ± 47.08 238.01 ± 60.01 *** 241.00 ± 64.51 223.50 ± 36.29
Ferritin (ng/mL) 159.27 ± 169.17 216.11 ± 175.04 110.34 ± 153.05 298.09 ± 209.02 ** 349.99 ± 208.82 135.91 ± 102.61
CRP (mg/dL) 0.55 ± 0.61 0.62 ± 0.76 0.51 ± 0.46 0.73 ± 0.75 0.75 ± 0.79 0.66 ± 0.67
SII 477.72 ± 260.63 441.22 ± 313.36 512.63 ± 198.80 715.91 ± 267.98 ** 757.45 ± 742.08 683.73 ± 261.09
PLR 205.78 ± 152.31 195.29 ± 149.00 226.56 ± 146.40 186.07 ± 75.56 193.51 ± 83.09 162.39 ± 37.50
NLR 2.04 ± 1.35 2.16 ± 1.66 2.23 ± 1.33 2.66 ± 1.41 2.71 ± 1.53 2.49 ± 0.88
Leucocytes
(×103/μL)
7.50 ± 1.84 8.06 ± 1.92 6.99 ± 1.64 6.17 ± 1.55 6.12 ± 1.58 6.32 ± 1.50
Hemoglobin (g/dL) 14.27 ± 1.58 14.82 ± 1.72 13.75 ± 1.25 14.83 ± 4.20 14.40 ± 1.35 16.14 ± 8.31
Platelets
(×103/mcL)
248.64 ± 68.68 247.72 ± 69.98 249.52 ± 68.98 258.37 ± 74.23 260.74 ± 77.17 250.82 ± 66.85
Lymphocytes
(×103/μL)
1.57 ± 0.80 1.66 ± 0.76 1.48 ± 0.84 1.46 ± 0.34 1.43 ± 0.36 1.56 ± 0.27
Neutrophils
(×103/μL)
2.86 ± 1.52 2.93 ± 1.70 2.79 ± 1.35 3.61 ± 1.31 3.66 ± 1.41 3.46 ± 1.00
Glycemia (mg/dL) 85.59 ± 13.85 100.55 ± 16.79 90.64 ± 8.18 93.11 ± 15.42 93.09 ± 16.15 93.17 ± 11.96
ALT (UI/L) 22.38 ± 15.62 21.80 ± 8.75 23.57 ± 25.85 30.19 ± 25.83 32.85 ± 28.05 20.44 ± 11.63
AST (UI/L) 22.83 ± 20.21 24.90 ± 21.05 20.57 ± 10.80 27.93 ± 17.71 30.78 ± 18.64 17.78 ± 8.61
Creatinin (mg/dL) 0.83 ± 0.20 0.95 ± 0.22 0.72 ± 0.07 0.88 ± 0.20 0.91 ± 0.20 0.75 ± 0.16
Comorbidities 75.55% 81.81% 69.56% 79.16% 81.57% 68.33%